# Impact of an Optimised Monitored Anesthesia on the Patients' Recovery After Cytoreduction Surgery Plus HIPEC

> **NCT04104334** · NA · TERMINATED · sponsor: **Ciusss de L'Est de l'Île de Montréal** · enrollment: 9 (actual)

## Conditions studied

- Hyperthermia
- Colorectal Neoplasms
- Oxaliplatin

## Interventions

- **DRUG:** Remifentanil infusion, desflurane titration and fluid infusion will be guided by NOL index, BIS index and Flotrac EV1000 system respectively
- **DRUG:** Remifentanil infusion and desflurane titration will be guided by anesthesia usual practices

## Key facts

- **NCT ID:** NCT04104334
- **Lead sponsor:** Ciusss de L'Est de l'Île de Montréal
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-05-08
- **Primary completion:** 2020-11-30
- **Final completion:** 2020-11-30
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Change in surgical practice and chemotherapy treatment by the surgery team
- **Last updated:** 2021-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04104334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04104334, "Impact of an Optimised Monitored Anesthesia on the Patients' Recovery After Cytoreduction Surgery Plus HIPEC". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04104334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*